These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35787522)

  • 1. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis.
    Nathan SD; Behr J; Cottin V; Lancaster L; Smith P; Deng CQ; Pearce N; Bell H; Peterson L; Flaherty KR
    BMJ Open Respir Res; 2022 Jul; 9(1):. PubMed ID: 35787522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
    Maher TM; Kreuter M; Lederer DJ; Brown KK; Wuyts W; Verbruggen N; Stutvoet S; Fieuw A; Ford P; Abi-Saab W; Wijsenbeek M
    BMJ Open Respir Res; 2019; 6(1):e000422. PubMed ID: 31179008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD).
    Maher TM; Assassi S; Azuma A; Cottin V; Hoffmann-Vold AM; Kreuter M; Oldham JM; Richeldi L; Valenzuela C; Wijsenbeek MS; Coeck C; Schlecker C; Voss F; Wachtlin D; Martinez FJ
    BMJ Open Respir Res; 2023 Sep; 10(1):. PubMed ID: 37709661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF).
    Richeldi L; Azuma A; Cottin V; Kreuter M; Maher TM; Martinez FJ; Oldham JM; Valenzuela C; Gordat M; Liu Y; Stowasser S; Zoz DF; Wijsenbeek MS
    BMJ Open Respir Res; 2023 Aug; 10(1):. PubMed ID: 37597969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
    Nathan SD; Waxman A; Rajagopal S; Case A; Johri S; DuBrock H; De La Zerda DJ; Sahay S; King C; Melendres-Groves L; Smith P; Shen E; Edwards LD; Nelsen A; Tapson VF
    Lancet Respir Med; 2021 Nov; 9(11):1266-1274. PubMed ID: 34214475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
    Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial.
    Popmihajlov Z; Sutherland DJ; Horan GS; Ghosh A; Lynch DA; Noble PW; Richeldi L; Reiss TF; Greenberg S
    BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35058236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA
    Corte TJ; Lancaster L; Swigris JJ; Maher TM; Goldin JG; Palmer SM; Suda T; Ogura T; Minnich A; Zhan X; Tirucherai GS; Elpers B; Xiao H; Watanabe H; Smith RA; Charles ED; Fischer A
    BMJ Open Respir Res; 2021 Dec; 8(1):. PubMed ID: 34969771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
    Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
    Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.
    Flaherty KR; Brown KK; Wells AU; Clerisme-Beaty E; Collard HR; Cottin V; Devaraj A; Inoue Y; Le Maulf F; Richeldi L; Schmidt H; Walsh S; Mezzanotte W; Schlenker-Herceg R
    BMJ Open Respir Res; 2017; 4(1):e000212. PubMed ID: 29018526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.
    Kreuter M; Wuyts WA; Wijsenbeek M; Bajwah S; Maher TM; Stowasser S; Male N; Stansen W; Schoof N; Orsatti L; Swigris J
    Respir Res; 2020 Jan; 21(1):36. PubMed ID: 32000772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
    Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
    Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
    Richeldi L; Schiffman C; Behr J; Inoue Y; Corte TJ; Cottin V; Jenkins RG; Nathan SD; Raghu G; Walsh SLF; Jayia PK; Kamath N; Martinez FJ
    Am J Respir Crit Care Med; 2024 May; 209(9):1132-1140. PubMed ID: 38354066
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
    Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
    Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.